Key result
Asian and ESH 2023 hypertension guidelines diverge to address distinct regional patient phenotypes.
Why the study?
Hypertension in the Asia-Pacific region shows high prevalence and distinct phenotypes compared to Western populations, challenging the applicability of Western guidelines.
This narrative review provides a critical comparison between the ESH 2023 hypertension guidelines and local Asian guidelines to address regional phenotypic differences and guide hypertension management in the Asia-Pacific context.
Answers are grounded in this paper and cite their sources.
Asian hypertension phenotypes differ from Western; supports region-specific guidelines but leaves open validation in dedicated trials.
Hypertension remains a major problem worldwide, especially across the Asia-Pacific region, which reports high prevalence rates and slow improvements in treatment rate and blood pressure (BP) control rate. Asian patients with hypertension may also vary with regard to phenotype and the epidemiology of the complications of hypertension, especially when compared with Western patients. Given these differences, Western guidelines may not necessarily be applicable to countries in the Asia Pacific. This narrative review aims to provide a critical comparison between the recently published European Society of Hypertension (ESH) 2023 guidelines and existing local guidelines in select Asian countries, offer expert opinion on how to fill gaps in the ESH 2023 guidelines for hypertension in the Asian context, and examine the need for harmonisation of hypertension guidelines worldwide. This review focuses on the definition and diagnosis of hypertension, the treatment thresholds and targets, and recommendations on the use of pharmacotherapy.
No takes yet. Share an insight, caveat, or question.
Sukonthasarn et al. (2024) conducted a review in Hypertension. ESH 2023 hypertension guidelines vs. Local Asian guidelines was evaluated. This narrative review compares the ESH 2023 hypertension guidelines with local Asian guidelines to address differences in patient phenotypes and optimize hypertension management in the Asian context.
Synapse has enriched 10 related papers. Consider them for comparative context: